🇺🇸 FDA
Patent

US 7521475

Chondropsin-class antitumor V-ATPase inhibitor compounds, compositions and methods of use thereof

granted A61PA61P13/00A61P15/08

Quick answer

US patent 7521475 (Chondropsin-class antitumor V-ATPase inhibitor compounds, compositions and methods of use thereof) held by The United States of America, as represented by the Department of Health and Human Services expires Mon Apr 16 2029 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Department of Health and Human Services
Grant date
Tue Apr 21 2009 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 16 2029 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
11
CPC classes
A61P, A61P13/00, A61P15/08, A61P19/08, A61P19/10